Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626KAS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS	4	OCT 03	MATHDI removed from STN
NEWS	5	OCT 04	CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS	6	OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS	7	OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools
NEWS	8	OCT 27	Free KWIC format extended in full-text databases
NEWS	9	OCT 27	DIOGENES content streamlined
NEWS	10	OCT 27	EPFULL enhanced with additional content
NEWS	11	NOV 14	CA/CAplus - Expanded coverage of German academic research

NEWS EXPRESS NOVEMBER 18 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:06:24 ON 27 NOV 2005

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 14:06:39 ON 27 NOV 2005

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 NOV 2005 HIGHEST RN 868737-05-7
DICTIONARY FILE UPDATES: 25 NOV 2005 HIGHEST RN 868737-05-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10724683.str



chain nodes :
10 18 19
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14 15 16
ring/chain nodes :
20
chain bonds :
10-11 18-19 19-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 11-12 11-16 12-13 13-14 14-15
15-16
exact/norm bonds :
5-7 6-9 7-8 8-9 18-19 19-20
exact bonds :
10-11
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
isolated ring systems :
containing 11 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS
20:CLASS 23:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 14:07:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     4610 TO ITERATE

 43.4% PROCESSED     2000 ITERATIONS                                 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        88129 TO    96271
PROJECTED ANSWERS:               2 TO      220

L2             2 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 14:07:14 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    93691 TO ITERATE

100.0% PROCESSED    93691 ITERATIONS                                48 ANSWERS
SEARCH TIME: 00.00.01

L3            48 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             161.33     161.54
```

FILE 'CAPLUS' ENTERED AT 14:07:21 ON 27 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 27 Nov 2005 VOL 143 ISS 23
FILE LAST UPDATED: 25 Nov 2005 (20051125/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 2 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:490721 CAPLUS
DOCUMENT NUMBER: 141:54192
TITLE: Preparation of aminoalkoxyindoles as 5-HT6-receptor ligands, in particular selective 5-HT6 antagonists, for treating CNS disorders
INVENTOR(S): Zhao, Shu-Hai
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050085	A1	20040617	WO 2003-EP13372	20031127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2508315	AA	20040617	CA 2003-2508315	20031127
EP 1569638	A1	20050907	EP 2003-782240	20031127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004132799	A1	20040708	US 2003-724683	20031201
PRIORITY APPLN. INFO.:			US 2002-430506P P	20021203
			WO 2003-EP13372 W	20031127

OTHER SOURCE(S): MARPAT 141:54192
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein m = 0-3; n = 0-2; each R1 = independently H, halo, halo/hetero/alkyl, OH and derivs., NO2, CN, NH2 and derivs., CONH2 and derivs., SO2NH2 and derivs., etc.; R2 = (un)substituted hetero/aryl; R3 = H, alkyl; X = (CR5R6)p; p = 2-3; R5, R6, R6, R8 = independently H, alkyl, or one of R5 and R6 together with one of R7 and R8 and the atoms therebetween = 4-6 membered heterocycle, etc.; and their pharmaceutically acceptable salts and prodrugs] were prepared as 5-HT6-receptor ligands, in particular selective 5-HT6 antagonists, for treating CNS disorders. For example, II•HCl was prepared in 4 steps from 3-methyl-2-nitrophenol and 1-(2-Chloroethyl)pyrrolidine hydrochloride by alkylation, cyclization, sulfanylation of the indole and oxidation with m-CPBA. Selected I displayed binding affinity values (pKi) for 5-HT6 receptors in the range of 7.7 to 8.4 in an in vitro radioligand binding study. I were tested and found to

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
be selective 5-HT6 antagonists.
IT 706784-16-9P, N-[2-[[3-(Benzenesulfonyl)-1H-indol-7-yl]oxy]ethyl]methylamine 706784-30-7P, [2-[[3-(2-Fluorobenzenesulfonyl)-1H-indol-7-yl]oxy]ethyl]amine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(5-HT6 antagonist; preparation of aminoalkoxyindoles as 5-HT6-receptor ligands, in particular selective 5-HT6 antagonists, for treating CNS disorders)
RN 706784-16-9 CAPLUS
CN Ethanamine, N-methyl-2-[[3-(phenylsulfonyl)-1H-indol-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 706784-30-7 CAPLUS
CN Ethanamine, 2-[[3-[(2-fluorophenyl)sulfonyl]-1H-indol-7-yl]oxy]- (9CI) (CA INDEX NAME)



IT 706783-64-4P, 3-Benzenesulfonyl-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole monohydrochloride 706783-65-5P, 3-(3-Chlorobenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole monohydrochloride 706783-66-6P, 3-(4-Chlorobenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole monohydrochloride 706783-67-7P, 3-(2,3-Dichlorobenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole monohydrochloride 706783-68-8P, 3-(2-Chlorobenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole monohydrochloride 706783-69-9P, 3-(3,4-Dichlorobenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole monohydrochloride 706783-70-2P, 3-(2-Fluorobenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole monohydrochloride 706783-71-3P, 3-(3-Fluorobenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole monohydrochloride 706783-72-4P, 3-(3-Methoxybenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole monohydrochloride 706783-73-5P, 3-(2-Methoxybenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole monohydrochloride 706783-74-6P,

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
N-[2-[(3-Benzenesulfonyl-1H-indol-7-yl)oxy]ethyl]dimethylamine monohydrochloride 706783-75-7P, N-[2-[[3-(2-Methoxybenzenesulfonyl)-1H-indol-7-yl]oxy]ethyl]dimethylamine monohydrochloride 706783-76-8P, N-[2-[[3-(2-Fluorobenzenesulfonyl)-1H-indol-7-yl]oxy]ethyl]dimethylamine monohydrochloride 706783-77-9P, N-[2-[[3-(2-Fluorobenzenesulfonyl)-1H-indol-7-yl]oxy]ethyl]methylamine monohydrochloride 706783-78-0P, N-[2-[(3-Benzenesulfonyl-1H-indol-7-yl)oxy]ethyl]methylamine monohydrochloride 706783-79-1P, N-[2-[(3-Benzenesulfonyl-1-methyl-1H-indol-7-yl)oxy]ethyl]methylamine monohydrochloride 706783-82-6P, N-[2-[(2-Benzenesulfonyl-1H-indol-4-yl)oxy]ethyl]methylamine monohydrochloride 706783-83-7P, N-[2-[(2-Benzenesulfonyl-1H-indol-7-yl)oxy]ethyl]methylamine monohydrochloride 706783-84-8P, 3-(2,5-Dichlorobenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole monohydrochloride 706783-85-9P, 2-Benzenesulfonyl-4-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole monohydrochloride 706783-87-1P, [2-[[3-(2-Fluorobenzenesulfonyl)-1H-indol-7-yl]oxy]ethyl]amine monohydrochloride 706784-06-7P, N-[2-[(3-(2-Fluorobenzenesulfonyl)-1H-indol-7-yl]oxy]ethyl]dimethylamine 706784-07-8P, 3-(2,5-Dichlorobenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole 706784-23-6P, 2-Benzenesulfonyl-4-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole 706784-35-2P, 3-Benzenesulfonyl-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole 706784-36-3P, 3-(3-Chlorobenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole 706784-37-4P, 3-(4-Chlorobenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole 706784-38-5P, 3-(2,3-Dichlorobenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole 706784-39-6P, 3-(2-Chlorobenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole 706784-40-9P, 3-(3,4-Dichlorobenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole 706784-41-0P, 3-(2-Fluorobenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole 706784-42-1P, 3-(3-Fluorobenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole 706784-43-2P, 3-(3-Methoxybenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole 706784-44-3P, 3-(2-Methoxybenzenesulfonyl)-7-[2-(pyrrolidin-1-yl)ethoxy]-1H-indole 706784-45-4P, N-[2-[(3-Benzenesulfonyl-1H-indol-7-yl)oxy]ethyl]dimethylamine 706784-46-5P, N-[2-[[3-(2-Methoxybenzenesulfonyl)-1H-indol-7-yl]oxy]ethyl]dimethylamine 706784-47-6P, N-[2-[[3-(2-Fluorobenzenesulfonyl)-1H-indol-7-yl]oxy]ethyl]methylamine 706784-48-7P, N-[2-[(3-Benzenesulfonyl-1-methyl-1H-indol-7-yl)oxy]ethyl]methylamine 706784-51-2P, N-[2-[(2-Benzenesulfonyl-1H-indol-4-yl)oxy]ethyl]methylamine 706784-52-3P, N-[2-[(2-Benzenesulfonyl-1H-indol-7-yl)oxy]ethyl]methylamine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(5-HT6 antagonist; prepn. of aminoalkoxyindoles as 5-HT6-receptor ligands, in particular selective 5-HT6 antagonists, for treating CNS disorders)
RN 706783-64-4 CAPLUS
CN 1H-Indole, 3-(phenylsulfonyl)-7-[2-(1-pyrrolidinyl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 706783-65-5 CAPLUS
CN 1H-Indole, 3-[(3-chlorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 706783-66-6 CAPLUS
CN 1H-Indole, 3-[(4-chlorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 706783-67-7 CAPLUS
CN 1H-Indole, 3-[(2,3-dichlorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 706783-68-8 CAPLUS
CN 1H-Indole, 3-[(2-chlorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 706783-71-3 CAPLUS
CN 1H-Indole, 3-[(3-fluorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 706783-72-4 CAPLUS
CN 1H-Indole, 3-[(3-methoxyphenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 706783-69-9 CAPLUS
CN 1H-Indole, 3-[(3,4-dichlorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 706783-70-2 CAPLUS
CN 1H-Indole, 3-[(2-fluorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 706783-73-5 CAPLUS
CN 1H-Indole, 3-[(2-methoxyphenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 706783-74-6 CAPLUS
CN Ethanamine, N,N-dimethyl-2-[[3-(phenylsulfonyl)-1H-indol-7-yl]oxy]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 706783-75-7 CAPLUS
CN Ethanamine, 2-[[3-[(2-methoxyphenyl)sulfonyl]-1H-indol-7-yl]oxy]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 706783-76-8 CAPLUS
CN Ethanamine, 2-[[3-[(2-fluorophenyl)sulfonyl]-1H-indol-7-yl]oxy]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 706783-77-9 CAPLUS
CN Ethanamine, 2-[[3-[(2-fluorophenyl)sulfonyl]-1H-indol-7-yl]oxy]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Ethanamine, N-methyl-2-[[2-(phenylsulfonyl)-1H-indol-4-yl]oxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 706783-83-7 CAPLUS
CN Ethanamine, N-methyl-2-[[2-(phenylsulfonyl)-1H-indol-7-yl]oxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 706783-84-8 CAPLUS
CN 1H-Indole, 3-[(2,5-dichlorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 706783-78-0 CAPLUS
CN Ethanamine, N-methyl-2-[[3-(phenylsulfonyl)-1H-indol-7-yl]oxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 706783-79-1 CAPLUS
CN Ethanamine, N-methyl-2-[[1-methyl-3-(phenylsulfonyl)-1H-indol-7-yl]oxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 706783-82-6 CAPLUS

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 706783-85-9 CAPLUS
CN 1H-Indole, 2-(phenylsulfonyl)-4-[2-(1-pyrrolidinyl)ethoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



⊖ HCl

RN 706783-87-1 CAPLUS
CN Ethanamine, 2-[[3-[(2-fluorophenyl)sulfonyl]-1H-indol-7-yl]oxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 706784-06-7 CAPLUS
CN Ethanamine, 2-[[3-[(2-fluorophenyl)sulfonyl]-1H-indol-7-yl]oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 706784-07-8 CAPLUS

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 1H-Indole, 3-[(2,5-dichlorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-(9CI) (CA INDEX NAME)



RN 706784-23-8 CAPLUS
CN 1H-Indole, 2-(phenylsulfonyl)-4-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 706784-35-2 CAPLUS
CN 1H-Indole, 3-(phenylsulfonyl)-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 706784-36-3 CAPLUS
CN 1H-Indole, 3-[(3-chlorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-(9CI) (CA INDEX NAME)



RN 706784-37-4 CAPLUS
CN 1H-Indole, 3-[(4-chlorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-(9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 706784-38-5 CAPLUS
CN 1H-Indole, 3-[(2,3-dichlorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-(9CI) (CA INDEX NAME)



RN 706784-39-6 CAPLUS
CN 1H-Indole, 3-[(2-chlorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-(9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 706784-40-9 CAPLUS
CN 1H-Indole, 3-[(3,4-dichlorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-(9CI) (CA INDEX NAME)



RN 706784-41-0 CAPLUS
CN 1H-Indole, 3-[(2-fluorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]-(9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 706784-42-1 CAPLUS
CN 1H-Indole, 3-[(3-fluorophenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 706784-43-2 CAPLUS
CN 1H-Indole, 3-[(3-methoxyphenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 706784-44-3 CAPLUS
CN 1H-Indole, 3-[(2-methoxyphenyl)sulfonyl]-7-[2-(1-pyrrolidinyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 706784-45-4 CAPLUS
CN Ethanamine, N,N-dimethyl-2-[[3-(phenylsulfonyl)-1H-indol-7-yl]oxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 706784-46-5 CAPLUS
CN Ethanamine, 2-[[3-[(2-methoxyphenyl)sulfonyl]-1H-indol-7-yl]oxy]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 706784-47-6 CAPLUS
CN Ethanamine, 2-[[3-[(2-fluorophenyl)sulfonyl]-1H-indol-7-yl]oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 706784-48-7 CAPLUS
CN Ethanamine, N-methyl-2-[[1-methyl-3-(phenylsulfonyl)-1H-indol-7-yl]oxy]- (9CI) (CA INDEX NAME)



RN 706784-51-2 CAPLUS
CN Ethanamine, N-methyl-2-[[2-(phenylsulfonyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 706784-52-3 CAPLUS

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Ethanamine, N-methyl-2-[[2-(phenylsulfonyl)-1H-indol-7-yl]oxy]- (9CI) (CA INDEX NAME)



IT 706784-13-6P, [2-[[3-[2-(Fluoro)benzenesulfonyl]-1H-indol-7-yl]oxy]ethyl](methyl)carbamic acid tert-butyl ester 706784-17-0P, [2-[[3-(2-Fluorobenzenesulfonyl]-1-methyl-1H-indol-7-yl]oxy]ethyl](methyl)carbamic acid tert-butyl ester 706784-20-5P, 2-Benzenesulfonyl-4-[2-[(tert-butoxycarbonyl)(methyl)amino]ethoxy]indole-1-carboxylic acid tert-butyl ester 706784-22-7P, 2-Benzenesulfonyl-7-[2-[(tert-butoxycarbonyl)(methyl)amino]ethoxy]indole-1-carboxylic acid tert-butyl ester 706784-27-2P, 2-Benzenesulfonyl-4-[2-(pyrrolidin-1-yl)ethoxy]indole-1-carboxylic acid tert-butyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of aminoalkoxyindoles as 5-HT6-receptor ligands,
in particular selective 5-HT6 antagonists, for treating CNS disorders)
RN 706784-13-6 CAPLUS
CN Carbamic acid, [2-[[3-[(2-fluorophenyl)sulfonyl]-1H-indol-7-yl]oxy]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 706784-17-0 CAPLUS
CN Carbamic acid, [2-[[3-[(2-fluorophenyl)sulfonyl]-1-methyl-1H-indol-7-yl]oxy]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



```
=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    10.33     171.87

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -1.46      -1.46

STN INTERNATIONAL LOGOFF AT 14:07:58 ON 27 NOV 2005
```